📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-29 18:33
87 analysed today
87
Today
136,095
All-time analysed
40,396
Positive
6,311
Negative
81,470
Neutral
7,850
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
BSE In-Principle Nod for ~₹7.44 Cr Preferential Allotment to Promoters via Loan Conversion
Sampre Nutritions has received in-principle approval from BSE Limited for issuing 17,70,710 equity shares (face value ₹5 each) to promoters on a preferential basis. The allotment is priced at not less than ₹42 per share, converting existing promoter unsecured loans into equity. At ₹42 per share, this translates to a debt-to-equity conversion of at least ₹7.44 crore, representing ~24% of the company's current market cap of ₹31 crore.
Confidence: HIGH
What changedBSE granted regulatory in-principle approval enabling the conversion of promoter unsecured debt into 17.71 lakh equity shares.
Why it mattersThe conversion reduces debt (total debt was ₹18 Cr) and strengthens the balance sheet while meaningfully raising promoter stake from a low 14.04%.
Shares to be allotted: 17,70,710Minimum issue price: INR 42Estimated conversion value: ~₹7.44 CrIssue value vs Market cap: ~24%Approval letter date: 28 August 2026
📅 Short termPositive sentiment as promoters demonstrate commitment by converting loans at a fixed minimum price of ₹42, significantly above current trading levels.
📈 Long termStrengthens net worth, reduces debt-servicing load, and addresses the structural risk of low promoter holding (14.04%).
⚠ Risk flags
- Dilution of non-promoter shareholding percentage upon allotment
- Geographic concentration of manufacturing operations in Medchal, Telangana
Key Highlights
BSE in-principle approval letter dated 28 August 2026 received for preferential issue.
Issuance and allotment of 17,70,710 equity shares (face value ₹5 each) to promoter/promoter group.
Minimum issue price fixed at ₹42 per share against conversion of promoter unsecured loans.
Total minimum loan conversion size stands at ~₹7.44 crore against total debt of ₹18 crore.
👀 What to Watch
Track the formal board allotment date and subsequent disclosure of revised promoter shareholding, which will rise from the current 14.04%.
233% Salary Hike Proposed for Director; 35th AGM Scheduled for Sept 4, 2026
Sampre Nutritions has convened its 35th Annual General Meeting (AGM) for September 4, 2026. The key agenda item is a special resolution to increase the annual remuneration of Whole-Time Director Vishal Ratan Gurbani from ₹18 lakh to ₹60 lakh, effective April 1, 2026. This proposed ₹60 lakh salary represents approximately 19.5% of the company's FY26 net profit of ₹3.08 crore. The board justifies the hike citing his expanded roles in business development and technical oversight.
Confidence: HIGH
What changedThe company is seeking shareholder approval to significantly increase the compensation of a key executive director for the remainder of his tenure ending August 2027.
Why it mattersFor a micro-cap company with ₹3.08 crore in annual profit, a ₹60 lakh salary for a single director is a significant overhead, though the board claims it is necessary for leadership retention and business expansion.
Proposed Annual Remuneration: ₹60,00,000Current Annual Remuneration: ₹18,00,000Proposed Salary vs FY26 PAT: ~19.5%Incremental Cost vs FY26 PAT: ~13.6%Promoter Holding: 14.04%
📅 Short termThe stock may see limited movement as the AGM notice is a procedural requirement, though the high salary hike proposal might be scrutinized by minority shareholders.
📈 Long termThe impact depends on whether the 'expanded responsibilities' of the director translate into higher revenue growth, which is critical given the recent 64.8% share price decline over 12 months.
⚠ Risk flags
- High executive remuneration relative to net profit
- Low promoter holding (14.04%)
- Significant historical share price volatility
Key Highlights
35th AGM scheduled for September 4, 2026, via video conferencing
Proposed 233% increase in remuneration for Whole-Time Director Vishal Ratan Gurbani
New proposed annual salary of ₹60,00,000, up from the current ₹18,00,000
The incremental cost of ₹42 lakh per annum represents roughly 13.6% of FY26 net profit
Cut-off date for e-voting and participation is set for August 28, 2026
👀 What to Watch
Investors should monitor the voting results of the special resolution regarding the director's remuneration hike, especially given the company's low promoter holding of 14.04%.
Q1 Revenue up 36% YoY to ₹14.85 Cr; Board proposes 233% hike in Director remuneration
Sampre Nutritions reported a 36.6% YoY increase in standalone revenue to ₹14.85 Cr for Q1 FY27, though net profit remained stagnant at ₹0.70 Cr. The company's operating expenses rose sharply, with employee benefit expenses increasing from ₹3.17 Cr to ₹5.10 Cr YoY. A significant proposal was made to increase the remuneration of Whole-Time Director Vishal Ratan Gurbani from ₹18 Lakhs to ₹60 Lakhs per annum, effective April 2026. This proposed salary represents approximately 15% of the company's TTM Net Profit of ₹4 Cr, which may draw investor scrutiny at the upcoming AGM.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results showing strong top-line growth but flat bottom-line performance, alongside a proposal for a significant executive pay increase.
Why it mattersFor a micro-cap company with ₹45 Cr market cap, a ₹60 Lakh director salary is a material expense. The flat profit despite 36% revenue growth indicates rising operational costs that need management attention.
Q1 FY27 Revenue: ₹14.85 CrYoY Revenue Growth: 36.6%Q1 FY27 Net Profit: ₹0.70 CrProposed WTD Remuneration: ₹60 LakhsRemuneration vs TTM PAT: ~15%
📅 Short termThe stock may see mixed sentiment as the market weighs healthy revenue growth against stagnant profits and increased management costs.
📈 Long termThe company needs to demonstrate operating leverage where revenue growth translates into higher profitability; currently, costs are scaling as fast as sales.
⚠ Risk flags
- Significant increase in executive remuneration relative to net profit
- Low promoter holding at 14.04%
- Stagnant net profit despite high revenue growth
Key Highlights
Standalone revenue from operations increased to ₹14.85 Cr in Q1 FY27 from ₹10.87 Cr in Q1 FY26.
Net profit for the quarter remained flat at ₹0.70 Cr compared to ₹0.71 Cr in the same period last year.
Proposed a 233% increase in remuneration for WTD Vishal Ratan Gurbani to ₹60,00,000 per annum.
Employee benefit expenses surged by 61% YoY to ₹5.10 Cr during the quarter.
Total expenses for the quarter rose to ₹14.12 Cr from ₹10.18 Cr in the previous year's corresponding quarter.
👀 What to Watch
Investors should monitor the shareholder voting results from the AGM on September 4, 2026, regarding the director's remuneration hike and observe if the strong revenue growth can eventually improve net margins.
233% Proposed Hike in Director Remuneration; Board Meeting on Aug 5 for Q1 Results
Sampre Nutritions has scheduled a board meeting on August 5, 2026, to approve Q1 FY27 results and finalize the 35th AGM notice. A key agenda item is the proposal to increase the remuneration of Whole-Time Director Vishal Gurbani from ₹18 lakhs to ₹60 lakhs per annum, effective retroactively from April 1, 2026. This 233% hike is significant for a company with a ₹50 crore market cap, representing approximately 15% of its TTM PAT of ₹4 crore. Investors should also note the low promoter holding of 14.04% and the sharp 68.7% decline in stock price over the last three months.
Confidence: HIGH
What changedThe company is proposing a significant increase in executive compensation while preparing to report its first-quarter earnings for the 2026-27 fiscal year.
Why it mattersA large increase in fixed management costs (15% of annual profits) in a micro-cap company with low promoter skin-in-the-game is a corporate governance signal that requires scrutiny by minority shareholders.
Proposed Remuneration: ₹60,00,000Current Remuneration: ₹18,00,000Remuneration Hike: 233%Remuneration vs TTM PAT: ~15%Board Meeting Date: 05 August 2026
📅 Short termThe stock may react to the Q1 earnings performance on August 5; the proposed pay hike may be viewed cautiously by the market given the recent price weakness.
📈 Long termLimited; the structural impact depends on whether the increased management cost is offset by sustained revenue and profit growth beyond the current ₹43 crore TTM revenue level.
⚠ Risk flags
- High executive remuneration relative to PAT (15%)
- Low promoter holding (14.04%)
- Significant recent stock price erosion (-68.7% in 3 months)
Key Highlights
Board meeting scheduled for August 5, 2026, to approve Q1 FY27 financial results.
Proposed 233% increase in annual remuneration for Whole-Time Director Vishal Gurbani.
Remuneration to rise from ₹18,00,000 to ₹60,00,000 per annum effective April 1, 2026.
Proposed annual salary of ₹60 lakhs represents ~15% of the TTM PAT of ₹4 crore.
Promoter holding remains low at 14.04% as of June 2026.
👀 What to Watch
Monitor the Q1 FY27 results on August 5 for operational performance and review the upcoming AGM notice for the management's justification of the substantial salary hike.
